Bristol-Myers Squibb Company
Key numbers
What the whole company is worth on the stock market.
Price ÷ last year's profit per share. Higher means investors pay more for each $1 of profit.
The same ratio using next year's expected profit.
How much the stock swings compared with the market: 1 moves like the market, 1.5 moves 50% more.
Yearly dividend as a share of the price.
What analysts say
28 analysts
Recent analyst actions
Financial health
Nine checks of profitability, debt and efficiency. 7–9 strong, 4–6 average, 0–3 weak.
Profitability and debt
Short-term assets ÷ short-term debts. Below 1 means more due within a year than on hand.
Fair value (DCF model)
A discounted-cash-flow model: what future cash flows are worth today. It is a model, not a promise.
Compared with similar companies
The company next to its sector peers.
| Company | Price | P/E | P/B | Market value |
|---|---|---|---|---|
| LLYEli Lilly and Company | 1,181.16 | 41.6 | 38.3 | $1.11T |
| JNJJohnson & Johnson | 262.62 | 29.9 | 6.1 | $630.04B |
| ABBVAbbVie Inc. | 279.28 | 77.4 | 94.4 | $488.55B |
| MRKMerck & Company, Inc. | 145.15 | 113.2 | 5.0 | $359.22B |
| UNHUnitedHealth Group Incorporated | 378.07 | 24.1 | 3.2 | $340.46B |
| TMOThermo Fisher Scientific Inc | 656.50 | 34.9 | 4.1 | $243.30B |
| AMGNAmgen Inc. | 414.58 | 25.7 | 20.4 | $224.29B |
| ABTAbbott Laboratories | 100.97 | 31.8 | 4.2 | $172.35B |
| PFEPfizer, Inc. | 28.29 | 37.2 | 1.6 | $161.19B |
| BMYBristol-Myers Squibb Company | 57.00 | 13.0 | 5.9 | $120.77B |
| Sector average | 42.9 | 18.3 |
About the company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to …
Data: Elcaro Core (Yahoo Finance, Binance, Treasury) · Information, not investment advice.